Schrödinger Q3 revenue beats expectations on milestone payment
SDGR•Schrödinger’s third-quarter revenue rose 19% year over year to $64.49 million, above the $47.26 million analyst consensus, helped by a milestone payment from Structure Therapeutics. The company raised its 2026 ACV and drug discovery revenue outlooks.
1. Revenue and loss
Schrödinger reported third-quarter revenue of $64.49 million, up 19% year over year and above analyst expectations of $47.26 million. Net loss widened to $37.71 million from $32.8 million a year earlier.
2. Outlook raised
The company raised its 2026 ACV guidance to $222 million-$232 million from $218 million-$228 million, and lifted its 2026 drug discovery revenue outlook to $75 million-$85 million from $65 million-$75 million. It expects 2026 operating expenses to be lower than in 2025.
3. Factors affecting results
Drug discovery revenue increased primarily because of a milestone payment from Structure Therapeutics. Software gross margin fell 2% as Schrödinger continued its transition to hosted licenses, while operating expenses declined 13% year over year.
